COVID-19 mortality risk for inflammatory arthritis patients: a cohort study using SAIL Databank
24 November 2022
A study of inflammatory arthritis (IA) patients found that shielding reduced the incidence of COVID-19. IA was not associated with an increased risk of dying within 28 days, but being vulnerable (advised to shield) and increased comorbidities were associated with an increased risk.
People with rheumatic diseases faced challenges during the COVID-19 pandemic, including concerns about higher risks of infection. Researchers formed a population-based cohort to investigate whether those with IA, their treatments and shielding status affected the risk of adverse outcomes from COVID-19 for the entire population of Wales.
During the COVID-19 pandemic, the lives of individuals with rheumatic diseases, such as rheumatoid arthritis, were greatly affected by concerns about the risk of infection. Having IA means the immune system is compromised and arthritis medication can also suppress the immune system. People with arthritis are also at increased risk of infection in general. The NHS advised high risk individuals to follow shielding practices including social distancing.
Researchers in Wales, supported by HDR UK and the National Centre for Population Health and Wellbeing Research Centre, undertook a retrospective, population-based cohort study. The study aimed to look at the risk of COVID-19 infection for people with IA and the potential for adverse outcomes.
They linked anonymised health data from the SAIL Databank, including primary and secondary care, Office for National Statistics Mortality and COVID-19 laboratory data, for the population of Wales. Individuals aged 18 years and over, who had tested positive for COVID-19 between March 2020 and May 2021 and had rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis formed the study cases and were compared to the general population who had tested positive for COVID-19.
The COVID-19 incidence rate was 3.5% in people with IA versus 6% in the general population. This showed that individuals with IA had a lower incidence of COVID-19, which was probably due to shielding.
IA was not associated with increased mortality following COVID-19 infection; however, being vulnerable (shielded), comorbidities such as diabetes and cancer, and other factors such as smoking and increasing age, were associated with increased risk of dying within 28 days of infection.
These key risk factors were used to identify individuals with IA at greater risk from COVID-19 and encourage those at risk to shield during high COVID-19 prevalence and highlight the importance of vaccination.
Dr Roxanne Cooksey, first author of the paper published in the journal Rheumatology, said:
“It is well known that people with inflammatory arthritis are at higher risk of infections, but we wanted to know how COVID played into that, particularly if some individuals with arthritis felt they should stop their medication out of concern. This study was novel because of our access to information on shielding from COVID data and being able to link it with primary and secondary care data, as well as death data, to see the impact on the arthritis community versus the general population.
“Our findings have been able to reassure people with inflammatory arthritis about the risk of COVID-19 while identifying those people that particularly need to shield in the community and to encourage vaccination for this group. Advising those most at risk means that the negative effects of shielding, such as social withdrawal due to social distancing could be mitigated to only those at greatest risk of severe COVID. Our next step is to revisit the study using linked data for the following year to explore health outcomes further following infection.”
New research questions reliability of studies into Lassa fever drug
28 February 2023
Researchers identified and re-analysed a series of studies to assess the reliability of the evidence backing the use of ribavirin as a treatment for Lassa fever.
Can we accurately forecast non-elective bed occupancy and admissions in the NHS? A time-series MSARIMA analysis of longitudinal data from an NHS Trust
1 July 2022
Hospitals need to be able to predict their capacity for admitting patients when planning elective surgeries. Researchers funded by HDR UK developed a new model for making forecasts that were more...
A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England
21 June 2022
Obesity dramatically increases the risk of death from COVID-19 but, the extent of this risk across different body weights and ethnic groups was not clear. Researchers using health and Census...